Curated CRC research, accessible, accurate, actionable

The CRC Digest

Tuesday, October 13, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ▪ SCREENING

  FDA grants breakthrough device designation to Natera's multi-cancer blood test

  The investigational assay analyzes cell-free DNA to screen for multiple cancer types, including colorectal cancer, from a single blood sample; no MCED test has yet received FDA approval. (Targeted Oncology)

• ▪ SCREENING

  Polygenic risk score, sex, and family history may help personalize screening start age

  In 353,118 UK Biobank participants, men had a 41% higher CRC risk than women, and each one-standard-deviation increase in polygenic risk score was associated with increased incidence; researchers propose risk-adapted screening ages based on these factors. (Int J Cancer)

• ♥ LIVING WITH CRC

  Delays in starting treatment linked to higher mortality in early-onset colorectal cancer

  A National Cancer Database study of 56,333 patients under 45 found that increased time to treatment initiation was associated with worse survival, with disparities in treatment delays identified across demographic groups. (JGH Open)

Today's research spans screening personalization and treatment timing in younger patients.